Bladder Cancer: Current Challenges and Future Directions
Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era of diagnosis and management of the disease. BC...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/57/8/749 |
| _version_ | 1797523029096398848 |
|---|---|
| author | Jakub Dobruch Maciej Oszczudłowski |
| author_facet | Jakub Dobruch Maciej Oszczudłowski |
| author_sort | Jakub Dobruch |
| collection | DOAJ |
| description | Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era of diagnosis and management of the disease. BCa-specific mortality started to decrease in the regions with a wide range of activities leading to greater social awareness of the risk factors and the decline in carcinogenic exposure. The urologic community refines the role of transurethral surgery towards more rigorous and high-quality techniques. New agents have been approved for patients with BCG failure who faced radical cystectomy so far. Although radical removal of the bladder is the gold standard for muscle invasive cancer management, the extent and clinical value of lymphadenectomy is currently heavily challenged in randomized trials. Furthermore, alternatives to perioperative chemotherapy have arisen to increase the likelihood of complete treatment delivery and successful oncological outcomes. Finally, improvements in molecular biology and our understanding of tumorigenesis open the era of personalized medicine in bladder cancer. In the present review, the status and future directions in bladder cancer epidemiology, diagnosis and management are thoroughly discussed. |
| first_indexed | 2024-03-10T08:37:38Z |
| format | Article |
| id | doaj.art-f3e86a7bf0974741a7f94fcf75bac6bf |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-10T08:37:38Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-f3e86a7bf0974741a7f94fcf75bac6bf2023-11-22T08:35:32ZengMDPI AGMedicina1010-660X1648-91442021-07-0157874910.3390/medicina57080749Bladder Cancer: Current Challenges and Future DirectionsJakub Dobruch0Maciej Oszczudłowski1Centre of Postgraduate Medical Education, Department of Urology, 00-416 Warsaw, PolandCentre of Postgraduate Medical Education, Department of Urology, 00-416 Warsaw, PolandBladder cancer (BCa) is the most common malignancy of the urinary tract and one of the most prevalent cancers worldwide. While the clinical approach to BCa has remained largely unchanged for many years, recent discoveries have paved the way to a new era of diagnosis and management of the disease. BCa-specific mortality started to decrease in the regions with a wide range of activities leading to greater social awareness of the risk factors and the decline in carcinogenic exposure. The urologic community refines the role of transurethral surgery towards more rigorous and high-quality techniques. New agents have been approved for patients with BCG failure who faced radical cystectomy so far. Although radical removal of the bladder is the gold standard for muscle invasive cancer management, the extent and clinical value of lymphadenectomy is currently heavily challenged in randomized trials. Furthermore, alternatives to perioperative chemotherapy have arisen to increase the likelihood of complete treatment delivery and successful oncological outcomes. Finally, improvements in molecular biology and our understanding of tumorigenesis open the era of personalized medicine in bladder cancer. In the present review, the status and future directions in bladder cancer epidemiology, diagnosis and management are thoroughly discussed.https://www.mdpi.com/1648-9144/57/8/749urinary bladder cancersurgical treatmentBCG failureperioperative chemotherapy |
| spellingShingle | Jakub Dobruch Maciej Oszczudłowski Bladder Cancer: Current Challenges and Future Directions Medicina urinary bladder cancer surgical treatment BCG failure perioperative chemotherapy |
| title | Bladder Cancer: Current Challenges and Future Directions |
| title_full | Bladder Cancer: Current Challenges and Future Directions |
| title_fullStr | Bladder Cancer: Current Challenges and Future Directions |
| title_full_unstemmed | Bladder Cancer: Current Challenges and Future Directions |
| title_short | Bladder Cancer: Current Challenges and Future Directions |
| title_sort | bladder cancer current challenges and future directions |
| topic | urinary bladder cancer surgical treatment BCG failure perioperative chemotherapy |
| url | https://www.mdpi.com/1648-9144/57/8/749 |
| work_keys_str_mv | AT jakubdobruch bladdercancercurrentchallengesandfuturedirections AT maciejoszczudłowski bladdercancercurrentchallengesandfuturedirections |